ReviewIntractable & rare diseases research2015
Liver transplantation and autoimmune hepatitis.
Review in Intractable & rare diseases research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Artificial intelligence predicts recurrent autoimmune hepatitis after liver transplantation in a multicenter cohort study.Hepatology communications · 2026Article
- Hepatobiliary and pancreatic manifestations in inflammatory bowel disease: an umbrella review of meta-analyses.Therapeutic advances in gastroenterology · 2025Review
- Trends of autoimmune liver disease inpatient hospitalization and mortality from 2011 to 2017: A United States nationwide analysis.World journal of hepatology · 2024Article
- Prolonged Anhepatic State as a Bridge to Retransplantation: A Challenging Case of a 35-Year-Old Male Liver Transplant Patient with a Temporary Portacaval Shunt.The American journal of case reports · 2023Article
- The Epidemiology of Pediatric Autoimmune Hepatitis in Scotland: A National Cohort Study.JPGN reports · 2022Article
- Do Patients with Autoimmune Conditions Have Less Access to Liver Transplantation despite Superior Outcomes?Journal of personalized medicine · 2022Article
- Rescue of autoimmune hepatitis by soluble MHC class II molecules in an altered concanavalin A-induced experimental model.Animal models and experimental medicine · 2020Article
- Autoimmune Hepatitis in Cuban Patients: A Retrospective Analysis of Clinical and Histological Profiles, Treatments, and Outcomes.Current therapeutic research, clinical and experimental · 2020Article
- Autoimmune Hepatitis-Immunologically Triggered Liver Pathogenesis-Diagnostic and Therapeutic Strategies.Journal of immunology research · 2019Review
- The Saudi association for the study of liver diseases and transplantation clinical practice guidelines for management of autoimmune hepatitis.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2018Article
- Autoimmune Hepatitis in the Elderly: Diagnosis and Pharmacologic Management.Drugs & aging · 2018Review
- [De novo autoimmune hepatitis after liver transplantation].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2016Article
- Clinical Presentation and Outcomes of Autoimmune Hepatitis in Inflammatory Bowel Disease.Digestive diseases and sciences · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver Transplantation (LT) is an effective treatment for patients with end-stage liver disease including autoimmune hepatitis (AIH). Indication for LT for AIH does not differ basically from other liver diseases including both acute and chronic types of disease progression, although it is reported to be an infrequent indication for LT worldwide due to the therapeutic advances of immunosuppression. The outcome following LT is feasible, with current patient and graft survival exceeding 75% at 5 years. Recurrent and de-novo AIH posttranslant has also been reported; and this seems to have important clinical implications because its management differs from the standard treatment for allograft rejection. In this review, we discuss the characteristics of AIH, focusing on the indication for LT and issues raised following LT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.